Glutathione: Side Effects

Safety Notice#

The safety profile of Glutathione in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

Summary table

Animals

• Chronic dosing in dogs up to 300 mg/kg/day for 26 weeks reported no significant adverse effects, suggesting a wide safety margin in this species; detailed frequency tables were not provided in the review.

Humans by route

• Oral: Randomized human trials largely report mild gastrointestinal symptoms. In a skin-lightening RCT using 250 mg twice daily for 4 weeks, flatulence was noted; no serious events were reported (no percentage stated). In a multicenter pediatric cystic fibrosis RCT (24 weeks), one participant in the glutathione arm discontinued due to decreased appetite and weight loss; overall serious adverse event rates did not differ from placebo. Reviews summarizing topical/oral trials for cosmetic purposes generally describe “no significant adverse effects,” but most studies were small and short-term.

• Intranasal: Early phase randomized studies in Parkinson’s disease reported no adverse events attributable to intranasal glutathione. In a later phase IIb trial (n=45; 100–200 mg three times daily for three months), one high-dose participant developed cardiomyopathy; no other consistent safety signals emerged (single case, frequency 1/45 overall).

• Inhaled/nebulized: Minor adverse effects are common, notably transient cough and an unpleasant odor. Clinically significant bronchoconstriction has been reported in sulfite-sensitive individuals with asthma; pre-use urine sulfite testing is recommended by the reviewer. Exact frequencies were not quantified across studies, but bronchospasm appears uncommon and concentrated in sulfite-sensitive asthma. Cystic fibrosis guidelines and reviews note bronchospasm as a concern with inhaled agents, consistent with these reports.

• Topical: Mostly local and mild. A 2% glutathione disulfide lotion trial reported mild facial erythema in one subject; case reports describe facial melanosis with certain glutathione soaps. Trials otherwise reported few or no systemic adverse effects.

• Intravenous (IV): Short-duration randomized trials using IV glutathione as a chemotherapy adjunct generally reported few or no adverse events attributable to glutathione over the dosing windows studied; however, safety data are short-term. For cosmetic/skin-lightening use, regulatory and review articles highlight serious risks. A narrative review cites an IV regimen (e.g., 1200 mg twice weekly for 6 weeks) with approximately 32% experiencing adverse events, including liver dysfunction, and at least one anaphylaxis case; standardization of dose and long-term safety are lacking. Reviews caution about severe cutaneous eruptions (up to SJS/TEN), renal dysfunction, thyroid dysfunction, and procedural infection risks (sepsis, endocarditis, air embolism) when administered in unregulated settings. Case reports include severe systemic inflammatory response syndrome requiring vasopressors after a compounded high-dose IV glutathione-containing infusion, with recovery in 48 hours. Another report describes anaphylaxis with Kounis syndrome after an IV preparation containing glutathione and other agents, highlighting potential for severe allergic cardiovascular events.

Strength of evidence and gaps

• Animal data directly on glutathione safety are limited but suggest low toxicity at high chronic doses in dogs.

• Oral and topical human studies generally show mild, infrequent adverse effects in short-term RCTs; long-term safety beyond 12–24 weeks remains insufficiently characterized.

• Inhaled use is often well tolerated but can trigger bronchospasm in sulfite-sensitive asthma; routine sulfite screening is suggested for at-risk patients.

• Intranasal trials show few adverse events overall, with a single cardiomyopathy case warranting cardiac vigilance in higher-dose regimens.

• Intravenous administration has the widest range of reported harms, including rare but severe events (anaphylaxis, hepatotoxicity, SIRS) and procedural risks, particularly in cosmetic/unregulated contexts; frequencies vary by setting, and robust long-term safety data are lacking.

• Animal: No significant adverse effects at 300 mg/kg/day for 26 weeks in dogs.

• Human oral/topical: Mostly mild and infrequent (GI upset, flatulence; occasional local erythema); one discontinuation for appetite/weight loss in a 24-week pediatric CF RCT; serious events not increased vs placebo.

• Human intranasal: Generally well tolerated; single cardiomyopathy case in a phase IIb PD trial (1/45 overall).

• Human inhaled: Transient cough/odor common; bronchospasm risk in sulfite‑sensitive asthma—screen before use.

• Human IV: Short-term oncology trials report few AEs, but cosmetic/unregulated IV use has reported AE rates up to ~32% with serious events including anaphylaxis and liver dysfunction; case reports document severe SIRS and anaphylaxis/Kounis syndrome. Long-term safety data are lacking.

Animal Study Safety Data#

Objective status update: We defined scope, searched and extracted animal and human adverse-effect data by route, and created a table artifact summarizing dose, frequency, and severity where available. We now provide a route- and species-stratified synthesis with citations.

Contraindications#

Objective and approach We reviewed contraindications and drug–interaction evidence for glutathione (GSH) across routes (oral, IV, inhaled), integrating documented clinical/pharmacologic data with mechanistic interactions (GST/GSH conjugation, redox, nitric oxide signaling), and emphasizing inhaled sulfite sensitivity, platinum chemotherapy interactions, nitrate tolerance, and acetaminophen metabolism.

Key contraindications and precautions

• Inhaled (nebulized/aerosolized) GSH: Sulfite-sensitive asthma is a clear contraindication due to reports of bronchoconstriction; pretesting for urinary sulfites is recommended before therapy. Most adverse effects reported are mild (odor, transient cough). Mechanistic context from asthma redox literature supports that airway GSH perturbations relate to hyperreactivity risk. The inhaled therapy review further advises against use for primary lung cancer.
• Hypersensitivity/excipient allergy: Avoid formulations in patients with known allergy to GSH products or excipients (e.g., sulfites).

Documented and mechanistically supported drug interactions

• Platinum chemotherapies (cisplatin, carboplatin): Elevated intracellular GSH and glutathione S‑transferase (GST), particularly GSTP1, reduce platinum efficacy by sequestration/inactivation of cisplatin, promotion of GSH adduct formation, and enhanced efflux, thereby limiting DNA adducts and promoting resistance. GSH depletion sensitizes cells; GSTP1 deletion increases sensitivity. Structural and functional data show GSTP1 can bind/inactivate cisplatin via reactive cysteines; tumor models link higher GSH/GST to resistance. Clinical implication: avoid systemic GSH supplementation during platinum therapy unless a clear rationale exists.
• Nitrovasodilators (nitroglycerin): Shifts in GSH redox toward oxidized glutathione (GSSG) increase protein S‑glutathionylation, inhibiting aldehyde dehydrogenase and attenuating NTG-stimulated cGMP formation, mimicking nitrate tolerance and reducing vasodilatory responsiveness. Clinical implication: therapies that markedly alter GSH/GSSG balance could modify nitrate responses; monitor effect if used concomitantly.
• Acetaminophen (paracetamol): The reactive metabolite NAPQI is detoxified via GSH (non-enzymatic and GST-catalyzed) to prevent hepatotoxicity; when GSH is depleted, injury occurs. N-acetylcysteine (NAC) replenishes GSH and is the established antidote; timing is critical for efficacy. Clinical implication: adequate hepatic GSH protects against toxicity; while NAC is standard of care, exogenous GSH could theoretically aid detoxification, though clinical data are limited.

Theoretical interactions based on mechanism

• Other electrophilic/alkylating agents (e.g., melphalan): GST‑mediated GSH conjugation can detoxify electrophilic chemotherapeutics and promote efflux, potentially reducing efficacy; GSH depletion often sensitizes such tumors.
• Inflammatory mediator pathways: GSH is a substrate for leukotriene C4 synthase; altering GSH availability may shift eicosanoid signaling and airway responses, relevant in asthma.
• NO/sGC signaling and thiol-sensitive enzymes: Increased protein S‑glutathionylation can inhibit thiol-dependent enzymes (e.g., ALDH2), perturbing nitrovasodilator bioactivation and NO/cGMP signaling.
• Nutritional/microbiome factors: Low sulfur amino acid intake or microbiome-derived p‑cresol can constrain sulfur pools and GSH synthesis, impacting detoxification capacity for drugs such as acetaminophen.

Summary table

Practical guidance

• Inhaled GSH: Avoid in sulfite‑sensitive asthma; screen for sulfites and monitor lung function if trialed; do not use for primary lung cancer.
• Systemic GSH during chemotherapy: Avoid concomitant use with platinum agents due to resistance risk via GSH/GST mechanisms.
• Nitrate therapy: Be aware that altered GSH redox status may reduce nitroglycerin responsiveness; monitor and adjust therapy if needed.
• Acetaminophen use/overdose: Ensure adequate GSH capacity; NAC is the evidence-based antidote to restore GSH and limit toxicity.

Toxicology#

We searched for primary toxicology reports specific to reduced glutathione (GSH) and found a subchronic intramuscular rat study providing organ toxicity and dose–response information; no retrievable primary LD50 or mutagenicity assays specific to GSH were identified in the current corpus. Key findings are summarized below, with an artifact table embedded for clarity.

Acute toxicity (LD50)

• No acute LD50 values specific to reduced glutathione (oral, intraperitoneal, or intravenous) were reported in the accessible material; thus, LD50 could not be determined from the retrieved evidence set.

Organ toxicity studies

• In rats given intramuscular reduced glutathione twice weekly for 13 weeks, 124 mg/kg produced no detectable hepatic, renal, or cardiac toxicity, whereas 248 mg/kg caused liver and kidney injury with biochemical (ALT, AST, urea, creatinine) and histopathologic changes; cardiac tissue showed no lesions. Hepatic changes partially resolved within two weeks after dosing stopped, while renal alterations persisted over that period.

Mutagenicity/genotoxicity testing

• No primary Ames test or in vivo micronucleus test data directly assessing reduced glutathione were retrievable in the gathered evidence; therefore, mutagenicity of GSH cannot be concluded from the current corpus.

Dose–response relationships

• Within the subchronic IM rat study, an apparent NOAEL of 124 mg/kg twice weekly and a LOAEL of 248 mg/kg twice weekly were observed for hepatic and renal toxicity endpoints. Dose-related oxidative stress markers supported these thresholds, with increased malondialdehyde and decreased tissue glutathione at the higher dose.

Limitations

• The evidence base located here is limited to one animal IM study for organ toxicity and dose–response and lacks acute LD50 and genotoxicity assays specific to GSH. Additional targeted searches of grey literature (e.g., SDS dossiers) and historical toxicology compendia may be required to obtain LD50 and mutagenicity data for reduced glutathione.

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• Glutathione overview and research guide
• Glutathione dosing protocols
• Glutathione risks and legal status